The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-07-01 Epub Date: 2024-06-26 DOI:10.1080/07357907.2024.2352454

Mohammadreza Bordbar, Mahnaz Hosseini-Bensenjan, Mehrab Sayadi, Omidreza Zekavat, Shayan Bordbar, Farnoosh Nozari, Sezaneh Haghpanah

引用次数: 0

Abstract

This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.

查看原文本刊更多论文

化疗后预防性使用 G-CSF 对急性髓性白血病患者复发率的影响：一项 Meta 分析

这项荟萃分析评估了急性髓性白血病（AML）患者化疗后预防性使用粒细胞集落刺激因子（G-CSF）的影响。总体而言，G-CSF（+）与G-CSF（-）患者的复发率、总生存率、无事件生存率和死亡率相似。然而，与G-CSF（-）组相比，接受G-CSF治疗的儿童和继发性AML患者的复发相对风险（RR）更高[RR，95%置信区间：1.26、1.04-1.52和1.12（1.02-1.24）]。对于急性髓细胞性白血病和继发性急性髓细胞性白血病的儿童患者，化疗后使用G-CSF治疗应慎重，因为这可能会增加复发风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.